UNSPSC 51434502: Valsartan

This classification denotes an angiotensin ii receptor antagonist with the molecular formula C24H29N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 80M03YXJ7I, chemically known as l-valine, n-(1-oxopentyl)-n-((2-(1h-tetrazol-5-yl)(1,1-biphenyl)-4-yl)methyl)- but generally known as valsartan, which bears US NIH Compound Identifier 60846. European Medicines Agency schedules Valsartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00017MIG.

UNSPSC 51434502 Valsartan, a Commodity code, encompasses pharmaceutical active ingredients and finished medications that state and local governments procure for emergency medical services, public health programs, and cooperative purchasing agreements across multiple jurisdictions. Recent state and local activity shows solicitations for both emergency advanced life support medications and broader generic pharmaceutical supply contracts through cooperative purchasing vehicles, indicating that the code captures both specialized acute-care drugs and commodity-level generic pharmaceutical products supplied to fire rescue services, health agencies, and multi-state procurement alliances.

The City of Tampa's Fire Rescue Department issued an IFB (Bid No. 26P00188) in April 2026 for advanced life support medications including Labetalol, Epinephrine, Adenosine, and Diltiazem, with an estimated contract value of $40,000 and a one-year term plus renewal options, using a 5 percent bid discount for Small Local Business Enterprises. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 (due March 26, 2026) to establish multi-year contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with awards effective July 1, 2026 and pricing weighted at 75 percent of evaluation criteria. The Texas Health and Human Services Commission issued an RFI in March 2026 to explore direct-to-manufacturer prescription fulfillment capabilities as a preliminary information-gathering phase prior to formal procurement. Activity appears concentrated among fire and emergency services, state health and human services agencies, and regional cooperative purchasing consortia in Texas, Minnesota, and Florida.